Objectives. To determine the longitudinal effects of TNF inhibitors on BMD and radiographic progression in patients with AS and to assess independent factors associated with increased BMD in the lumbar spine.
Introduction
AS is a chronic inflammatory rheumatic disease characterized by inflammation of the SI joint and spine. The initial symptom is inflammatory back pain, but the hallmark of advanced AS is spinal ankylosis, which is related to new bone formation. Paradoxically, osteoporosis (OP) is also a well-known feature of AS, and osteoporotic fractures are more prevalent in AS patients than in the general population [1, 2] .
Bone loss associated with inflammatory joint diseases is induced by pro-inflammatory cytokines. The main pro-inflammatory cytokines, TNF-a, IL-1 and IL-6, promote subclinical bone resorption and OP [3] . RA, the most prevalent form of chronic inflammatory arthritis, is characterized by periarticular osteopenia, which precedes the development of erosions and joint destruction. TNF inhibitors not only improve disease activity, but also retard radiographic joint destruction [46] . Additionally, TNF inhibitors decrease the levels of bone resorption marker, b-isomerized carboxy terminal telopeptide of type 1 collagen, and prevent bone loss [7] . Treatment with TNF inhibitors is both safe and effective for reducing disease activity in AS patients [810] . AS patients receiving TNF inhibitor therapy show an increase in BMD in the lumbar spine and femur, which is accompanied by a dramatic improvement in disease activity and a decrease in inflammation [11, 12] . Despite the strong antiinflammatory effects of TNF blockers in AS, these agents have no effect on new bone formation, such as syndesmophytes [1315] ; indeed, a recent study suggests an increase in new bone formation following resolution of inflammation in patients treated with TNF inhibitors [16] . Spinal syndesmophytes cause an artefactual increase in lumbar spine BMD as measured by DXA [17] . A recent longitudinal study reported that increased spinal BMD is related to radiographic progression, such as sclerosis and syndesmophytes in AS patients [18] . However, the effects of TNF inhibitors on lumbar spine BMD after accounting for the influence of radiographic progression have not yet been fully evaluated.
Therefore the present study investigated the long-term effects of TNF inhibitor therapy on BMD and radiographic progression in patients with AS. We also analysed whether TNF inhibitor therapy was independently associated with increases in lumbar spine BMD in multivariate analysis after adjusting for radiographic progression.
Methods

Patients and clinical assessment
The study cohort comprised 63 AS patients who fulfilled the modified New York criteria for the classification of AS [19] and who were followed up at the Department of Rheumatology, Seoul St Mary's Hospital. The participants' written consent was obtained according to the Declaration of Helsinki and the study was approved by the ethics committee of the Seoul St Mary's Hospital (KCMC078BR276). Twenty-six patients were treated with TNF inhibitors and 37 were not. All were taking NSAIDs and/or MTX or SSZ. Patients with other forms of SpA or those with a history of neuroendocrine disorders, chronic renal disease and excessive alcohol intake were excluded. None of the patients in this study took CSs, calcium or vitamin D. All women included in the study were pre-menopausal. The patients' detailed drug histories and clinical assessments were obtained. Demographic and clinical data were obtained at baseline. Inflammatory activity was measured according to the ESR and CRP level at each time point: baseline, 1 year and 2 years. BMD measurements BMD was measured using DXA (Lumbar Prodigy densitometer, Madison, WI, USA) at baseline, 1 year and 2 years. BMD was measured in the lumbar spine (L1L4) and the right hip (femoral neck and total proximal femur), and was expressed as follows: the number of grams of bone mineral per square centimetre (g/cm 2 ) and the number of S.D.s above or below the mean for a healthy 30-year-old adult of the same sex and ethnicity as the patient (t-score). Data were assessed against the manufacturer's reference values.
Radiographic scoring
Radiographs of the lumbar spine were obtained at baseline and at 2 years of follow-up, and radiographs of the SI joints were obtained at baseline. Images were evaluated by an experienced investigator blinded to the patient data and chronology. Sacroiliitis was assessed by viewing images of the SI joint and was graded according to the New York criteria. Radiographic scoring in the lumbar spine was assessed by two methods: the Stoke AS Spinal Score (SASSS) [20] and the modified Stoke AS Spire Score (mSASSS) [21] . To obtain the SASSS, the anterior and posterior vertebral corners of the lumbar (T12 lower to S1 upper) spinal segments were graded on a scale of 03, where 0 = no abnormality; 1 = erosion, sclerosis or squaring of the vertebral body; 2 = presence of a syndesmophyte; and 3 = presence of a bridging syndesmophyte (total score range 072). The mSASSS was obtained by grading only the anterior vertebral corners of the lumbar (T12 lower or S1 upper) spinal segments (because the lumbar spine radiographs were assessed without the cervical radiographs; total score range 036). The number of syndesmophytes was assessed by both SASSS and mSASSS.
Statistical analysis
The 2 -test and an independent samples t-test were used to compare categorical and continuous variables between the TNF inhibitor group and non-TNF inhibitor group. Comparisons between baseline BMD and BMD at 1 and 2 years were examined using paired t-test. Correlation between the variables was examined with Pearson correlation coefficients. The longitudinal association between changes in BMD and TNF inhibitor administration was assessed using linear mixed modelling, which included data obtained at baseline and after 1 and 2 years of follow-up. Radiographic progressions were compared between the patients in the TNF inhibitor group and non-TNF inhibitor group using analysis of covariance, adjusted for baseline radiographic progression scores on the change in those from baseline to 2 years. The change in BMD was the dependent variable, gender and TNF inhibitor therapy were explanatory fixed effects, and patient age and baseline BMD were random effects. Potential associations between changes in BMD and demographic variables (age, gender, disease duration and HLA-B27) and diseaserelated variables (ESR, SASSS and grade of sacroiliitis) were first explored by univariate analysis. Multivariate analyses were performed using multivariate linear regression (Enter procedure), incorporating all variables with a P < 0.10 in univariate analysis as explanatory variables. Analyses were performed using SPSS (version 18.0; SPSS Inc., Chicago, IL, USA). P < 0.05 was considered statistically significant.
Results
Baseline characteristics
Patient characteristics are presented in Table 1 . Twenty-six patients received TNF inhibitors. TNF inhibitor www.rheumatology.oxfordjournals.org
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TNF inhibitor on BMD and radiographic change in AS treatment was initiated at the discretion of the attending rheumatologist, but only after the failure of two NSAID treatments. Patients receiving TNF inhibitors were treated with either infliximab (3 mg/kg; n = 5), etanercept (25 mg twice a week; n = 18) or adalimumab (40 mg every other week; n = 3); all patients received NSAIDs on demand.
Patients not receiving TNF inhibitors (n = 37) were treated with NSAIDs ± SSZ or MTX. The baseline characteristics of all the patients, along with those after stratification according to TNF inhibitor therapy, are shown in Table 1 . The only significant difference between the two groups was that the TNF inhibitor-treated group showed a significantly higher baseline grade of sacroiliitis than the non-TNF inhibitor-treated group (P = 0.08).
Changes in BMD induced by TNF inhibitor therapy Table 2 shows the mean BMD in the lumbar spine, femoral neck and the total proximal femur at each time point for all patients and for the groups treated or not treated with TNF inhibitors. Significant increases in BMD in the lumbar spine and total proximal femur (6.3 and 1.8%, respectively) were observed in the total patient group (n = 63) at the 2-year follow-up (P < 0.001 and P = 0.014). Continuous increases in mean lumbar spine BMD at 1 and 2 years relative to those at baseline were observed in both the TNF inhibitor-treated and non-treated groups (Table 2) . However, significant BMD gains in the total proximal femur were maintained for 2 years only in patients receiving TNF inhibitors. The mean BMD in the total proximal femur increased by 2.0% at 1 year relative to baseline in the TNF inhibitor group, but fell by 0.1% in the non-TNF inhibitor group. The increase in total proximal femur BMD was maintained over 2 years in patients receiving TNF inhibitors (P = 0.007). There was no significant increase in BMD in the femoral neck in either the TNF inhibitor-treated or non-treated groups, or in the total proximal femur of the non-TNF inhibitor group.
Efficacy of TNF inhibitors on BMD increases in the lumbar spine and total proximal femur Lumbar spine BMD increased consistently over 2 years in both the TNF inhibitor-treated and non-treated groups. Mean BMD gains in the lumbar spine increased by 6.8% at 1 year relative to baseline and by 3.7% at 2 years (relative to the 1-year values) in the TNF inhibitor-treated group, and by 2.7 and 0.3%, respectively, in the non-treated group. The rate of increase was significantly higher in the TNF inhibitor-treated group than in the non-treated group (P < 0.001; Fig. 1 ). Mean BMD gains at the total proximal femur increased by 2.0% at 1 year relative to baseline and by 1.5% at 2 years (relative to the 1-year values) in the TNF inhibitor-treated group. The increase in total proximal femur BMD was also significantly greater over 2 years in the TNF inhibitor-treated group than in the non-treated group (P = 0.024).
Relationship between the 2-year changes in BMD and inflammation Two-year changes in lumbar spine BMD correlated with a reduction in the ESR (r = 0.253, P = 0.048) in the group containing all patients (Table 3 ). In analyses stratified for TNF inhibitor therapy, the 2-year reduction in ESR correlated with changes in lumbar spine BMD (r = 0.475, P = 0.019) and the number of newly formed syndesmophytes (r = 0.422, P = 0.036) in the TNF inhibitor-treated group, but showed no correlation with these parameters in the non-treated group. Two-year changes in BMD at the femoral neck and total proximal femur did not correlate with a reduction in the ESR. There was no correlation between the 2-year reduction in CRP levels and changes in BMD at all sites and between the 2-year reduction in CRP levels and radiographic progression.
Influence of TNF inhibitors on 2-year radiographic progression in the lumbar spine Table 4 shows the changes in structural progression and the mean number of newly formed syndesmophytes in the lumbar spine according to TNF inhibitor therapy. In patients receiving TNF inhibitors, the mean change in the SASSS at 2 years was 5.5, and the mean number of new syndesmophytes was 1.4. In the non-TNF inhibitor group, the mean change in the SASSS was 3.1, and the mean number of new syndesmophytes was 0.8. The rate of radiographic progression in the lumbar spine as measured by the SASSS was significantly different between the two groups at 2 years (P = 0.05), however, the rate of new syndesmophyte formation was not significantly different. When we compared the mean changes in the mSASSS, no significant difference in radiographic progression was found. Additionally, there was no significant difference in syndesmophyte formation (consistent results were obtained using both the SASSS and the mSASSS). Figure 2 shows the changes in the SASSS in subgroup analysis according to bisphosphonate treatment. In patients receiving TNF inhibitors, the change in the SASSS was significantly different between the two groups (P < 0.01); however, the mean change in the SASSS according to additive bisphosphonate treatment in non-TNF inhibitor group was not significantly different.
Multivariate analysis Table 5 shows the results of univariate and multivariate linear regression analysis. In univariate analysis, BMD increases in the lumbar spine were associated with gender, Error bars represent the mean (S.E.).
www.rheumatology.oxfordjournals.org 721 TNF inhibitor on BMD and radiographic change in AS the grade of sacroiliitis at baseline, TNF inhibitor therapy, an increase in the SASSS and a reduction in the ESR. Multivariate analysis revealed that TNF inhibitor therapy and an increase in the SASSS were independently associated with increases in lumbar spine BMD (b = 5.29, P = 0.009 and b = 0.87, P < 0.001, respectively).
Discussion
The present study assessed the effects of TNF inhibitors on BMD and radiographic progression in AS patients. The results showed that TNF inhibitor treatment significantly improved BMD, but also was associated with increased radiographic progression.
Reductions in BMD are an early event in AS [22] . OP occurs in AS patients due to reduced levels of physical activity, decreased spine mobility related to pain, stiffness and ankylosis, and/or subclinical gut involvement; other genetic factors and inflammatory activity are also involved [3] . Patients treated with TNF inhibitors show an increase in BMD as well as a reduction in pain and inflammation [23, 24] . In the present 2-year follow-up study of 63 AS patients we observed 6.3 and 1.8% increases in BMD in the lumbar spine and total proximal femur, respectively. These increases were maintained at both sites by long-term TNF inhibitor therapy, however, no increase in BMD was noted in the femoral proximal femur in non-TNF inhibitor-treated patients. In the measurement of BMD using DXA, vertebral sclerosis and syndesmophytes are related with the artefactual increase in the lumbar spine 
FIG. 2
Changes in the SASSS in TNF inhibitor-treated and -untreated groups stratified according to bisphosphonate treatment.
*P-value calculated using analysis of covariance model with therapy as a factor and baseline SASSS as a covariate. BP: bisphosphonate; TNFi: TNF inhibitor. NS: not significant. [25] . Previous longitudinal studies did not account for the effects of radiographic progression when explaining increases in lumbar spine BMD [11, 26] . Therefore we analysed the effects of TNF inhibitors on lumbar spine BMD by multivariate regression analysis after adjusting for radiographic progression. The results showed that treatment with TNF inhibitors resulted in a significant increase in lumbar spine BMD. Recent studies showed no significant difference in mSASSS increases in AS patients treated for 2 years with TNF inhibitors compared with those in control patients [1315] . Our data also suggested that mSASSS increases in the lumbar spine were no different between TNF inhibitor-treated patients and controls. Despite the fact that mSASSS is a validated assessment tool for AS and is used as the standard scale in many clinical trials, it is limited in that it only reflects the anterior elements of the cervical and lumbar spines, without taking into account the posterior elements or the thoracic spine. Spinal MRI in AS patients shows that inflammation is primarily seen at the anterior and posterior vertebral corners. Vertebral corner inflammatory lesions seen on MRI lead to new bone formation [16, 27] . Therefore, scoring the posterior elements as well as the anterior elements is important when assessing radiographic progression. The SASSS is more appropriate for measuring radiographic changes in both the anterior and posterior elements, therefore, to enable more exact analysis of the lumbar spine, we used the SASSS scoring system. The results revealed increased radiographic progression in patients receiving TNF inhibitors. Although TNF inhibitor alone does not significantly influence radiographic progression, concurrent treatment of TNF inhibitors and bisphosphonates increased radiographic progression. Additionally, the significant relationship between the number of new syndesmophyte and resolution of inflammation was observed in only the TNF inhibitor group. These findings raise the possibility that TNF inhibitors may increase new bone formation following the resolution of inflammation.
TNF-a is associated with bone resorption in patients with inflammatory arthritis. TNF-a acts on osteoblasts to promote receptor activator of nuclear factor k-B ligand (RANKL) expression and thus stimulates osteoclastogenesis and increases osteoclast activity [3] . It is also associated with bone formation. A previous study proposed that TNF acts as a brake on new bone formation by regulating Dickkopf-related protein 1, which inhibits pathways leading to new bone formation through the Wnt and BMP proteins [12] . These findings suggest that TNF inhibitors may not only decrease bone resorption, but also increase bone formation.
The present study identified a correlation between 2-year changes in lumbar spine BMD and a reduction in the ESR in TNF inhibitor-treated AS patients. This is consistent with data published in a previous report [11] . On the other hand, there was no correlation between BMD changes and reduced inflammation in patients not receiving TNF inhibitors. The formation of new syndesmophytes in the 63 AS patients in the present study was not related to a reduction in systemic inflammation following treatment. However, separate analysis of the TNF inhibitortreated and non-treated groups showed that reductions in ESR correlated with the number of new syndesmophytes only in the TNF inhibitor-treated group. Recent studies report that more syndesmophytes form at inflamed vertebral edges than at non-inflamed edges [27, 28] . Additionally, other studies show that the formation of new syndesmophytes is associated with resolution of inflammation after TNF inhibitor treatment [16, 27] . Our findings suggest that increased radiographic progression in TNF inhibitor-treated patients may be due to TNF acting as a brake on bone formation rather than the resolution of inflammation within the vertebral corner inflammatory lesions.
Our results are not consistent with earlier studies done by van der Heijde [1315] . Some factors seem to influence the discordance. A large number of patients in this study are under treatment with bisphosphonates. Bisphosphonates are not part of the standard treatment guidelines for AS, but we use bisphosphonates for treatment of OP, not disease activity in AS patients. The guideline for AS patients with OP is not established yet. At present, exercise regimens and bisphosphonates are widely used [29] . Concurrent treatment with TNF 
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TNF inhibitor on BMD and radiographic change in AS inhibitors and bisphophonates raises the possibility that the additive effect of bisphosphonates in bone formation may influence radiographic progression in patients who received TNF inhibitors. To exclude the possibility that bisphosphonates act as a confounding factor, future studies with larger subject numbers are required. Also, the prevalence of OP in this study was about 40%. It is higher than the prevalence in previous studies, 18.725% [3032] . Because it is known that OP in AS is related to disease activity and inflammation, the higher prevalence of OP may be because the patients in our study have more severe disease. Also, the significant difference in radiographic grade of sacroiliitis at baseline raises the possibility of a difference in disease severity between the two groups. It suggests that the difference in disease severity may influence radiographic progression.
Maksymowych [12] hypothesized that very early inflammatory lesions resolve after treatment with TNF inhibitors and before the induction of reparative changes, whereas accelerated repair leading to new bone formation is observed after treatment with TNF inhibitors in moremature inflammatory lesions in which the reparative process is already under way. This supposes that very early inflammatory lesions resolve completely without any sequelae if TNF inhibitors are introduced before the signalling pathways involved in the reparative processes are activated. However, new bone will be formed if TNF inhibitors are administered after the signalling pathways are activated. Our data showed that TNF inhibitor-treated patients had a higher grade of sacroiliitis at baseline than non-TNF inhibitor-treated patients, meaning that patients receiving TNF inhibitors were likely to experience more severe and persistent inflammation. It may be possible that their inflammatory lesions were more advanced and that reparative signalling pathways had already been activated, leading to new bone formation. Therefore the resolution of inflammation in more mature lesions following TNF inhibitor treatment in the present study may have caused the radiographic progression.
Taken together, our data illustrate the paradoxical effects of TNF inhibitors on AS patients: on the one hand, they increase bone density, and on the other hand, they are associated with radiographic progression in the lumbar spine. The increases in both BMD and radiographic progression may be explained by the specific effects of TNF inhibitors, or by a bystander effect, in which inflammation is reduced by blocking TNF, or a combination of both. Because TNF inhibitors may actually increase new bone formation, novel and more efficient treatments are needed that reduce disease activity and inhibit new bone formation.
One possible limitation of this study is the use of the SASSS system to quantify disease progression. This system is limited in that it takes into account the structural changes in the lumbar spine without assessment of the cervical or thoracic spines. Although we used mSASSS in the lumbar spine, it may not fully reflect radiographic changes at the cervical spine. Also, we measured ESR and CRP at baseline and 2 years to analyse the relationship between the resolution of inflammation and radiographic progression, but there is a limitation in reflecting persistent inflammation. The cumulative effect of inflammation is more important to bone loss or radiographic progression than a single measure. Additionally, the number of subjects enrolled in the present study was too small to definitively identify changes in radiographic progression. A more direct comparison between TNF inhibitors and standard therapies needs to be performed in a randomized double-blinded, placebo-controlled trial.
In conclusion, TNF inhibitors significantly increased BMD in the lumbar spine and total proximal femur of AS patients over 2 years after adjusting for radiographic progression. However, TNF inhibitors also increased the degree of structural damage in the lumbar spine following resolution of inflammation, especially in patients treated with bisphosphonates. Long-term prospective randomized studies will need to be performed to further assess the full impact of TNF inhibitors on radiographic progression.
Rheumatology key messages
. TNF inhibitors increased BMD in the lumbar spine and total proximal femur in AS patients. . TNF inhibitors may increase radiographic progression of the lumbar spine in AS patients treated with bisphosphonates.
